Defining the Rules of Breast Cancer Cell Traffic Through Bone
定义乳腺癌细胞通过骨运输的规则
基本信息
- 批准号:9239952
- 负责人:
- 金额:$ 38.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-01-09 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant ChemotherapyAdjuvant TherapyApoptoticAreaBackBiopsyBlood CirculationBlood VesselsBone MarrowBone Marrow InvolvementBone marrow biopsyBreast Cancer CellBreast Cancer PatientCXCR4 geneCancer BiologyCancer EtiologyCause of DeathCell Adhesion MoleculesCell CycleCell SurvivalCell surfaceCellsCessation of lifeChemosensitizationClinicalCytotoxic ChemotherapyCytotoxic agentDataDiagnosisDiseaseE-SelectinEnvironmentFlushingHematopoietic stem cellsHomingHormonalIn VitroIndividualIntegrinsInterventionKnowledgeLaboratoriesLigandsMalignant NeoplasmsMediatingMetastatic Neoplasm to the BoneMethodsMicrometastasisMicroscopyMolecularMolecular and Cellular BiologyMorphologyMovementMusNeoplasm MetastasisOrganPathway interactionsPatientsPeripheralPhenotypeProliferatingRecurrent diseaseRelapseResistanceResolutionRoleSelectinsShelter facilitySignal TransductionSiteSourceStaining methodStainsStem cellsStromal Cell-Derived Factor 1TestingTherapeuticTimeTissuesTropismWomanWorkXenograft Modelbasebonecancer cellcell motilitycytokinedesignhormone therapyin vivoin vivo imaginginhibitor/antagonistmalignant breast neoplasmmortalitynew therapeutic targetpreventprotective effecttrafficking
项目摘要
ABSTRACT
The major cause of death from breast cancer is metastatic relapse, which most commonly occurs first in
the bone. Bone marrow (BM) biopsies performed on women with early stage breast cancer have shown that
small, clinically unapparent “micrometastases” are actually present at the time of diagnosis in many patients.
These micrometastases can survive in the face of adjuvant chemotherapy and lay dormant for years before
they become proliferative, causing overt metastatic disease. At this stage, disease becomes incurable.
Our increasing understanding of breast cancer biology has revealed to us the importance of the host
tissue in creating a receptive and protective environment for metastases. Preliminary data from our lab using
mouse xenograft models show that breast cancer cells (BCCs) metastasize to and lay dormant in unique
perivascular hematopoietic progenitor and stem cell (HSPC) niches. The blood vessels in these regions are
distinguished by their sinusoidal morphology and their high basal expression of the adhesion molecule E-
selectin, and the cytokine SDF-1. Using highly specific E-selectin and CXCR4 inhibitors, we have identified that
E-selectin and SDF-1 orchestrate opposing roles in BCC trafficking. While E-selectin interactions are critical for
allowing BCC entry in BM, SDF-1/CXCR4 anchors BCCs to the microenvironment and its inhibition induces
mobilization of dormant micrometastases into circulation. Moreover, our immunohistochemical studies of
biopsies performed on patients with micrometastatic BM involvement show that dormant metastases reside
adjacent to SDF-1+ vasculature. Based on these data, we hypothesize that dormant BCCs shelter within
unique peri-sinusoidal vascular BM niches from which they are able to dynamically transit back-and-forth to the
peripheral circulation as well as to alternative, pro-proliferative microenvironments within the bone. We also
hypothesize that interventions such as CXCR4 and E-selectin inhibition can flush dormant BCCs from the
protective sinusoidal niche, making them susceptible to cytotoxic or hormonal therapies. To test these
hypotheses, we will use single cell resolution, video rate in vivo microscopy in mouse xenograft models to track
BCC migration through BM in real time. In combination with in vitro molecular and cellular biology approaches,
we will 1) Investigate the signals that critically regulate BCC metastatic entry in bone; 2) Study the molecular
mechanisms that regulate BCC exit from bone metastatic sites into peripheral circulation and the impact of
mobilization on BCC signaling and viability; and 3) Understand how cross talk with the peri-sinusoidal BM
vascular niche mediates BCC dormancy and sensitivity to chemo- and hormonal therapies. Knowledge gained
from this work will identify fundamental mechanisms governing the dynamic movement of micrometastatic
BCCs and will suggest therapeutic methods to target supportive crosstalk between BM and dormant breast
cancer.
摘要
乳腺癌的主要死因是转移性复发,最常发生在
骨头。对早期乳腺癌妇女进行的骨髓活组织检查显示,
临床上看不出来的微小“微转移”实际上在许多患者确诊时就已经存在。
这些微转移瘤可以在辅助化疗的情况下存活,并潜伏多年。
它们变得增殖,导致明显的转移性疾病。在这个阶段,疾病变得无法治愈。
我们对乳腺癌生物学的不断加深的了解向我们揭示了宿主的重要性
组织在为转移创造易于接受和保护的环境中发挥作用。来自我们实验室的初步数据使用
小鼠异种移植模型显示乳腺癌细胞(BCC)转移到唯一的
血管周围造血祖细胞和干细胞(HSPC)的壁龛。这些区域的血管是
区别于它们的正弦形态和它们高基础表达的黏附分子E-
选择素和细胞因子SDF-1。使用高度特异的E-选择素和CXCR4抑制剂,我们已经确定
E-选择素和SDF-1在BCC贩运中扮演相反的角色。虽然E-选择素的相互作用对
允许BCC进入BM,SDF-1/CXCR4将BCC锚定到微环境及其抑制诱导
动员潜伏的微转移瘤进入循环。此外,我们的免疫组织化学研究
对骨髓微转移患者进行的活组织检查显示存在潜伏性转移。
邻近SDF-1+血管构筑。根据这些数据,我们假设休眠的国库银行藏匿在
独特的窦周血管BM龛,它们能够从那里动态地来回传递到
外周循环以及骨骼内替代的、促进增殖的微环境。我们也
假设CXCR4和E-选择素抑制等干预措施可以将休眠的BCC从
保护性的正弦利基,使它们容易受到细胞毒性或激素治疗的影响。为了测试这些
假设,我们将使用单细胞分辨率、视频速率在活体显微镜下对小鼠异种移植模型进行追踪
通过黑石实时迁移BCC。结合体外分子和细胞生物学方法,
我们将1)研究关键调控BCC骨转移进入的信号;2)研究分子
BCC从骨转移灶出口到外周循环的调节机制及对其的影响
对基底细胞癌信号和生存能力的动员;以及3)了解与窦周骨髓的串扰
血管壁龛调节基底细胞休眠和对化疗和激素治疗的敏感性。获得的知识
通过这项工作将确定控制微转移动态运动的基本机制
BCC并将建议针对BM和休眠乳房之间的支持性串音的治疗方法
癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dorothy A Sipkins其他文献
Dorothy A Sipkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dorothy A Sipkins', 18)}}的其他基金
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis
识别和利用导致骨到脑膜乳腺癌转移的肿瘤与宿主相互作用的治疗脆弱性
- 批准号:
10826488 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10455633 - 财政年份:2021
- 资助金额:
$ 38.55万 - 项目类别:
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10289183 - 财政年份:2021
- 资助金额:
$ 38.55万 - 项目类别:
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
定义和靶向中枢神经系统软脑膜转移的新途径
- 批准号:
10322127 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
定义和针对中枢神经系统软脑膜转移的新途径
- 批准号:
10553654 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
定义和靶向中枢神经系统软脑膜转移的新途径
- 批准号:
9888134 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
定义和针对中枢神经系统软脑膜转移的新途径
- 批准号:
10079480 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Defining the Rules of Breast Cancer Cell Traffic Through Bone
定义乳腺癌细胞通过骨运输的规则
- 批准号:
10368923 - 财政年份:2017
- 资助金额:
$ 38.55万 - 项目类别:
Defining the Rules of Breast Cancer Cell Traffic Through Bone
定义乳腺癌细胞通过骨运输的规则
- 批准号:
10066311 - 财政年份:2017
- 资助金额:
$ 38.55万 - 项目类别:
Stem cell, tumor and bone marrow microenvironment cross-talk in vivo
体内干细胞、肿瘤和骨髓微环境的串扰
- 批准号:
7430502 - 财政年份:2007
- 资助金额:
$ 38.55万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 38.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 38.55万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 38.55万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 38.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 38.55万 - 项目类别:
Operating Grants